Pain reduction in validated rat pain models: radio frequency spectrum targeted at the low and ultra-low ends using the emulate® delivery system

ABSTRACT

EMulate Therapeutics, Inc. (EMTx) has developed a technology to deliver time-varying magnetic fields as WAV files, emitted in the extremely low through the low spectrum of radio frequencies (DC to 22 kHz), that can be applied to regulate pain sensation. These low power fields (~30-70 milli-Gauss AC RMS) are delivered via a portable, light-weight wearable device (Voyager). A contract third-party animal research organization (ANS Biotech, S.A.) specializing in validated rat pain models, ran the studies independently of the authors. Here we report that a subset of signals demonstrated a statistically significant effect in reducing the sensation of pain in rat models for visceral pain, neuropathic pain and inflammatory pain. Furthermore, removing frequencies above 6 kHz in the original signals improve the pain reducing effects of the unmodified signal.

KEYWORDS:

• magnetic
• pain
• rat
• radio
• analgesia
• frequency

Acknowledgments

We would like to acknowledge Yassine Darbaky, Violette Maffre, Marielle Ardid and the scientist/technicians at ANS Biotech, S.A. for their careful work and excellent attention to details. We would also like to acknowledge the members of the EMulate Therapeutics team (Chris Rivera, Steve Pope and David Matteson) and Dr. Len Wisneski for their thoughtful reviews and comments on the paper. This work was supported in totality by private funds raised by EMulate Therapeutics inc.

Disclosure statement

Both XAF and BMB are stock-holders of EMulate Therapeutics Inc. XAF is an employee of EMulate Therapeutics and BMB is a contractor for EMulate Therapeutics. LL is a contractor of EMulate Therapeutics Inc.

Data availability

Results from work done at ANS Biotech can be made available upon request to the corresponding author.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/15368378.2022.2131568

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This work was supported byEMulate Therapeutics, Inc.;